

More complaints than findings - Long-term pulmonary function in children and adolescents after COVID-19

Leona Knoke ^{1,2,3}, Anne Schlegtendal ^{1,2}, Christoph Maier ¹, Lynn Eitner ¹, Thomas Lücke ¹, Folke Brinkmann ¹

¹ University Children's Hospital, Ruhr-University Bochum, 44791 Bochum, Germany

² Contributed equally as first authors.

³ This work is part of the thesis of Leona Knoke.

Corresponding author

Folke Brinkmann

Department of Paediatric Pneumology, University Children's Hospital, Ruhr-University Bochum

Alexandrinenstraße 5, 44791 Bochum, Germany

e-mail: folke.brinkmann@rub.de

phone: +49 234-509-2611

fax: +49 234-509-2612

Article type: Original Research Article

Acknowledgements

We are grateful to the healthcare team at the Children's University Hospital Bochum, especially Chantal Matenar whose efforts were fundamental to this work. We would like to thank all the patients and families involved.

Contributors

CM, TL, FB developed the study design and protocol and supervised patient management. LK drafted the manuscript with contributions of intellectual content from AS, LE, CM, TL and FB. LK, AS, LE collected the data. LK, AS, CM and FB examined the data and undertook statistical analyses. All authors have seen and approved the final version of the manuscript. FB is guarantor and attests that all named authors and contributors meet authorship criteria and that no others meeting such criteria have been omitted.

Funding

This study has partially been funded by the Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung [BMBF], trial registration 01KI20173).

Clinical trial ID

DRKS00022434, German clinical trial register

Competing interests

None declared

Patient consent for publication

Not required.

Ethics approval

Ethical approval was provided by the Ethics Committee of the Ruhr-University Bochum, Germany (No. 20-6927).

Checklist for the appropriate study type

STROBE and RECORD checklists are included as supplementary appendices.

Data availability statement

Data are available upon reasonable request.

ABSTRACT

Background: The frequency of persistent symptoms after coronavirus disease 2019 (COVID-19) in adults varies from 4.5% to 87%. Pulmonary function can also show long-term impairment in adults: 10% of hospitalised adults had reduced spirometry values, and 24% had decreased diffusion capacity. To date, only preliminary evidence is available on persistent respiratory sequelae in children and adolescents, therefore our objective was to examine the long-term effects of COVID-19 on pulmonary function in this age group.

Methods: Multiple-breath washout, body plethysmography, and diffusion capacity testing were performed after an average of 2.6 months (range 0.4–6.0) following COVID-19 in 73 children and adolescents (age 5–18 years) with different disease severity. Cases were compared to 45 controls with and without infection within six months prior to assessment after exclusion of severe acute respiratory coronavirus-2 infection (SARS-CoV-2).

Results: Of the 19 patients (27.1%) who complained about persistent or newly emerged symptoms since COVID-19, 8 (11.4%) reported respiratory symptoms. Comparing patients with COVID-19 to controls, no significant differences were detected in frequency of abnormal pulmonary function (COVID-19: 12, 16.4%; controls: 12, 27.7%; OR 0.54, 95% CI 0.22–1.34). Only two patients with persistent respiratory symptoms showed abnormal pulmonary function. Multivariate analysis revealed reduced forced vital capacity ($p=0.045$) in patients with severe infection regardless of SARS-CoV-2 infection.

Discussion: Pulmonary function is rarely impaired in children and adolescents after COVID-19, except of those with severe infection. The discrepancy between persistent respiratory symptoms and normal pulmonary function suggests a different underlying pathology such as dysfunctional breathing.

INTRODUCTION

The clinical course of children and adolescents with SARS-CoV-2 infection is mostly less severe than in adults [1].

Long-COVID sums up all symptoms that persist or newly emerge four weeks to beyond twelve weeks after acute SARS-CoV-2 infection [2].

In one study, up to 87% of adults hospitalised due to COVID-19 infection reported persistent symptoms (for example fatigue, dyspnoea, cough, gastrointestinal symptoms) about two months after COVID-19 infection [3]. In another cohort with in- and outpatients in the same age range, only 4.5% were still symptomatic with similar symptoms after eight weeks [1]. There is only preliminary evidence of persistent symptoms in children: Buonsenso et al. described that 52.7% of their study population reported at least one persistent symptom equal to or more than four months after SARS-CoV-2 infection, while 14.7% stated they suffered persistent respiratory problems [4].

Long-lasting deterioration in pulmonary function has been described in adults [5–7]. Lerum et al. reported that about 10% of adults hospitalised with COVID-19 had reduced values for forced vital capacity (FVC) and forced expiratory volume in one second (FEV₁), and 24% showed significantly reduced diffusion capacity at a three-month follow-up visit [5]. However, frequency and extent of long-term changes in pulmonary function in children and adolescents following COVID-19 infection are barely examined. Bottino et al performed spirometry and diffusion capacity testing in seven children about two months after recovery from mild SARS-CoV-2 infection and did not find any abnormalities [8].

To evaluate the impact of respiratory sequelae in children is important given the fact that most children worldwide will potentially get infected with SARS-CoV-2 as long as vaccines are predominantly reserved for adults and high-risk groups.

We analysed pulmonary function of children and adolescents after COVID-19 and compared their results to a group of controls after exclusion of SARS-CoV-2 infection.

PATIENTS AND METHODS

Study design and population

We conducted a single-centre, cross-sectional, prospective study to assess pulmonary function after COVID-19 in children and adolescents from 5 to 18 years of age. This study was part of a still ongoing study at the University Children's Hospital of Bochum, Germany, assessing rates of SARS-CoV-2 seroconversion in children and adolescents in western Germany (CorKid).

We recruited from August 2020 to March 2021 and included subjects with positive SARS-CoV-2 antibodies tested in the CorKid study, as well as in- and outpatients who tested positive for SARS-

CoV-2 using polymerase chain reaction (PCR) at the University Children's Hospital of Bochum or in an outpatient practice in the region. Children with negative antibodies for SARS-CoV-2 and no other evidence of SARS-CoV-2 infection from the CorKid study served as controls. Exclusion criteria were inability to perform lung function testing and missing written consent.

The subjects and/or their guardians answered questionnaires regarding their medical history, especially acute and chronic pulmonary diseases, as well as current and previous medications. Any infections within six months prior to the assessment and their date, duration and symptoms, as well as PCR test results for SARS-CoV-2 were recorded. We also documented persistent symptoms after COVID-19 infection in the COVID-19 group.

According to these data, we subdivided the COVID-19 group into those who were symptomatic and those who were asymptomatic, and showed signs of respiratory tract infections (if cough, rhinitis, sore throat and/or dyspnoea was confirmed) and other types. Severity of infection was subclassified into severe and non-severe. An infection was considered severe if it included dyspnoea, fever $>38.5^{\circ}\text{C}$ for >5 days, bronchitis or pneumoniae, and/or hospitalisation >1 day.

Patients were classified as having chronic lung disease if they had a known medically diagnosed pulmonary disease like bronchial asthma or if they had one of the following: recurrent wheeze, pneumonia in the year before measurement, previous or current use of inhaled steroids for at least 4 weeks or long-lasting productive cough (≥ 8 weeks).

We also divided the subjects into two groups (follow-up 0–3 and 4–6 months) depending on the interval between infection and assessment.

Pulmonary function testing

Body plethysmography and diffusing capacity testing for carbon monoxide (CO) were performed using MasterScreen Body/Diff (Vyair, Hoechberg, Germany) according to American Thoracic Society/European Respiratory Society guidelines [9, 10]. We measured FEV₁, FVC, mean expiratory flow at 75% (MEF₇₅) and MEF₂₅, as well as diffusing capacity of the lung for carbon monoxide (DLCO) and diffusing capacity divided by the alveolar volume (DLCO/VA) standardised to Z-scores using Global Lung Initiative reference values [11, 12]. DLCO and DLCO/VA were adjusted for haemoglobin levels. N₂ multiple-breath washout was measured using Exhalyzer D (EcoMedics AG, Duernten, Switzerland) according to current guidelines [13]. We reported the Lung Clearance Index at 2.5% of starting concentration (LCI_{2.5%}) as recommended.

All pulmonary function tests were done by specially trained staff and assessed by two paediatric pneumologists blinded to the patient's SARS-CoV-2 status.

Pulmonary function was defined as abnormal, if at least one measured parameter was pathological (LCl_{2.5%} >7.9, FVC Z-score, FEV₁ Z-score, MEF₇₅ Z-score, MEF₂₅ Z-score, DLCO Z-score, DLCO/VA Z-score <-1.96) or there was at least one borderline parameter (LCl_{2.5%} >7.0, FVC Z-score, FEV₁ Z-score, MEF₇₅ Z-score, MEF₂₅ Z-score, DLCO Z-score, DLCO/VA Z-score <-1 ≥ -1.96) for two different pulmonary function tests (N₂ multiple-breath washout, body plethysmography, diffusion capacity).

Imaging of the lungs was performed only when clinically necessary.

Statistics

Descriptive statistics: We calculated mean, median, range and standard deviation for continuous variables. Categorical values were expressed as absolute values and percentages.

Inferential statistics: Odds Ratios (ORs) and 95% confidence intervals (95% CIs) were calculated for categorical values. Normal distribution was proven for all pulmonary function parameters either using the Komolgorov-Smirnov test or the Levene test. Independent *t*-test or analysis of variance (ANOVA) was used for between-group comparisons. Post-hoc analysis was performed using least significant difference. All statistical analysis were performed using SPSS version 27 (SPSS for Windows, SPSS Inc., Chicago, IL, USA). A *p*-value of 0.05 or less was considered statistically significant.

Ethical approval

The ethics committee of the Ruhr-University, Bochum, Germany, approved the project (register number: 20-6927). All participants and/or their parents were informed about the study and provided written informed consent.

RESULTS

We enrolled 73 subjects with confirmed SARS-CoV-2 infection, 26 (35.6%) of whom were symptomatic during the acute phase. Of the 45 subjects who served as controls, 14 (31.1%) had any symptomatic infection other than COVID-19 within six months before the assessment.

Excluding six COVID-19 patients without PCR, the mean interval between infection and date of testing was similar in both groups (COVID-19: 2.59 months (range 0.4–6.0); controls: 3.43 months (range 1.03–6.3)).

The epidemiological data were similar in both groups (see Table 1a).

Table 1a: Epidemiological data

Epidemiological data	All	COVID-19 patients		All	Controls		OR (95% CI) [‡]
		Symptomatic infection within the past 6 months	Asymptomatic infection within the past 6 months		Any other infection within the past 6 months	No infection within the past 6 months	
N	73	27*	46	45	14	31	
Sex, female	38 (52.0)	14 (51.9)	24 (52.2)	28 (62.2)	11 (78.6)	17 (54.8)	0.66 (0.31–1.41)
Age, years, mean ± SD	10.82 (± 3.25)	10.48 (± 3.19)	11.02 (± 3.3)	10 (± 3.5)	9.14 (± 3.39)	10.39 (± 3.53)	
Age group, 5–8 years	21 (28.8)	7 (25.9)	14 (30.4)	18 (40)	8 (57.1)	10 (32.3)	0.61 (0.28–1.32)
Age group, 9–12 years	29 (39.7)	13 (48.2)	16 (34.8)	16 (35.6)	2 (14.3)	14 (45.2)	1.19 (0.55–2.58)
Age group, 13–18 years	23 (31.5)	7 (25.9)	16 (34.8)	11 (24.4)	4 (28.6)	7 (22.6)	1.42 (0.61–3.29)
Gestational age, premature	4 (5.6) ²	2 (8) ²	2 (4.4)	5 (11.1)	2 (14.3)	3 (9.7)	0.48 (0.12–1.88)
Neonatal intensive care unit	13 (18.3) ²	8 (32) ²	5 (10.9)	4 (8.9)	2 (14.3)	2 (6.5)	2.3 (0.7–7.55)
With oxygen supplementation	4 (5.6) ²	2 (8) ²	2 (4.4)	1 (2.2)	0	1 (3.2)	2.63 (0.28–24.29)
Pulmonary disease, previous or current	17 (23.3)	8 (29.6)	9 (19.6)	10 (22.2)	3 (21.4)	7 (22.6)	1.06 (0.44–2.58)

SD, standard deviation; OR, odds ratio; CI, confidence interval

Data are expressed as *n* (%), unless specified otherwise

* For one patient, the documented symptomatic infection within six months prior to the assessment was probably not SARS-CoV-2 infection

¹ e.g., cough or dyspnoea; ² missing values *n* = 2, ‡ OR and 95% CI calculated for all COVID-19 vs. all controls

Disease severity and type of infection did not show significant differences between the two groups. However, 70.4% ($n = 19$) of children and adolescents with symptomatic SARS-CoV-2 infection did not have respiratory symptoms, whereas 92.9% ($n = 13$) of infections in the control group involved the respiratory tract. Rhinitis and cough were significant more often in the control group than in the COVID-19 group (rhinitis: OR 0.14, 95% CI 0.03–0.62; cough: OR 0.24, 95% CI 0.06–0.95). Other assessed symptoms did not show significance between the two groups (see Table 1b for more information).

Table 1b: Infection characteristics

Infection characteristics	COVID-19 patients	Controls	OR (95% CI)
	Symptomatic infection within the past 6 months	Any other infection within the past 6 months	
N	27*	14	
Respiratory tract infection	19 (70.4)	13 (92.9)	0.18 (0.02–1.64)
Severe infection	8 (29.6)	2 (14.3)	2.53 (0.46–13.96)
With dyspnoea	3 (11.1)	1 (7.1)	1.63 (0.15–17.24)
With bronchitis or pneumonia	1 (3.7)	2 (14.3)	0.23 (0.02–2.8)
With fever >38.5°C for >5 days	3 (11.1)	0	-
With need for hospitalisation	4 (14.8)	0	-
Symptoms			
Fever >38.5°C	14 (51.9)	4 (28.6)	2.69 (0.67–10.74)
Rhinitis	9 (33.3)	11 (78.6)	0.14 (0.03–0.62)
Sore throat	12 (44.4)	9 (64.3)	0.44 (0.12–1.68)
Cough	10 (37)	10 (71.4)	0.24 (0.06–0.95)
Dyspnoea	3 (11.1)	1 (7.1)	1.63 (0.15–17.24)
Headache	12 (44.4)	5 (35.7)	1.44 (0.38–5.45)
Limb pain	11 (40.7)	5 (35.7)	1.24 (0.33–4.71)
Fatigue	23 (85.2)	9 (64.3)	3.19 (0.7–14.66)
Diarrhoea/Vomiting	4 (14.8)	2 (14.3)	1.04 (0.17–6.54)
Loss of smell/taste	5 (18.5)	0	-

OR, odds ratio, CI confidence interval

Data are expressed as n (%), unless specified otherwise

* For one patient, the documented symptomatic infection within six months prior to the assessment was probably not the SARS-CoV-2 infection

Long-term complaints

Nineteen (27.1%, data were only available for 70 subjects) children and adolescents of the COVID-19 group reported persistent or newly emerged symptoms after SARS-CoV-2 infection. Eight (11.4%) reported at least one respiratory symptom, six (8.6%) of whom suffered ongoing breathing problems and two (2.9%) persistent cough. The mean age of children and adolescents with respiratory long-term symptoms was similar to all patients with SARS-CoV-2 infection (all COVID-19: 10.82 ± 3.25 , patients with respiratory long-term symptoms: 11.75 ± 3.92 [mean \pm standard deviation in years]). In two patients, these respiratory problems newly emerged after asymptomatic SARS-CoV-2 infection. Ten (14.3%) suffered from fatigue; five patients (7.1%) had both persistent respiratory symptoms and fatigue syndrome.

Pulmonary function testing

Comparing the two groups of children and adolescents with and without SARS-CoV-2 infection, there were no significant differences in $LCI_{2.5\%}$ (absolute) and age-related Z-scores of FVC, FEV_1 , MEF_{75} , MEF_{25} , DLCO and DLCO/VA. Details are shown in Table 2 and Figure 1.

Table 2: Pulmonary function parameters

Pulmonary function parameters	COVID-19 patients			Controls		
	All	Symptomatic infection within the past 6 months	Asymptomatic infection within the past 6 months	All	Any other infection within the past 6 months	No infection within the past 6 months
N₂ Multiple-breath washout						
N	68	27	41	40	11	29
LCI _{2.5} , absolute	6.75 ± 0.73	6.79 ± 0.62	6.72 ± 0.81	6.88 ± 0.61	6.79 ± 0.47	6.91 ± 0.66
Abnormal values	3 (4.4)	1 (3.7)	2 (4.9)	3 (7.5)	0	3 (10.3)
Body plethysmography						
N	71	26	45	45	14	31
FVC, Z-score	-0.21 ± 1.06	-0.26 ± 1.04	-0.19 ± 1.08	-0.21 ± 1.22	-0.25 ± 1.53	-0.19 ± 1.08
Abnormal values	5 (7)	1 (3.9)	4 (8.9)	5 (11.1)	2 (14.3)	3 (9.7)
FEV ₁ , Z-score	0.3 ± 1.04	0.34 ± 1.04	0.28 ± 1.05	0.27 ± 1.19	0.2 ± 1.34	0.3 ± 1.13
Abnormal values	0	0	0	1 (2.2)	1 (7.1)	0
MEF ₇₅ , Z-score	0.28 ± 1.1	-0.03 ± 1.13	0.46 ± 1.05	0.12 ± 1.09	-0.35 ± 1.38	0.34 ± 0.87
Abnormal values	3 (4.2)	2 (7.7)	1 (2.2)	1 (2.2)	1 (7.1)	0
MEF ₂₅ , Z-score	0.86 ± 0.94	0.91 ± 0.68	0.83 ± 1.07	1.19 ± 1	1.04 ± 0.88	1.26 ± 1.06
Abnormal values	0	0	0	0	0	0
Diffusion capacity						
N	38	10	28	27	4	23
DLCO, Z-score	2.03 ± 2.35	2.56 ± 2.27	1.84 ± 2.39	1.55 ± 1.91	2.74 ± 2.7	1.35 ± 1.74
Abnormal values	2 (5.3)	0	2 (7.1)	1 (3.7)	0	1 (4.4)
DLCO/VA, Z-score	0.02 ± 0.76	-0.11 ± 1.09	0.07 ± 0.62	-0.21 ± 0.94	0.05 ± 1.39	-0.25 ± 0.88
Abnormal values	0	0	0	0	0	0

LCI_{2.5}, Lung Clearance Index at 2.5% of starting concentration; FVC, Forced Vital Capacity; FEV₁, Forced Expiratory Volume in the first Second; MEF, Mean Expiratory Flows at different pulmonary volume levels (75, 25); DLCO, Diffusing Capacity of the lungs for Carbon Monoxide; VA, Alveolar Volume
 All pulmonary function parameters are presented as mean ± standard deviation. Abnormal values are presented in *n* (%).




Figure 1: Depiction of pulmonary function parameters for COVID-19 and controls. Boxplots show medians, quartiles, minimum and maximum values. The dots represent the individual values of participants.

Participants with severe infection within the last six months are marked as red squares.

LCI_{2.5%}, Lung Clearance Index at 2.5% of starting concentration; FVC, Forced Vital Capacity; FEV₁, Forced Expiratory Volume in the first Second; DLCO, Diffusion Capacity of the lungs for Carbon Monoxide

Subjects suffering from severe infection within six months prior to the assessment had significant reduction in FVC ($p = 0.045$) and MEF_{75} ($p = 0.002$) compared to those with non-severe infection and asymptomatic infection. Neither site of infection nor COVID-19 status influenced pulmonary function (see Figure 2). MEF_{25} , DLCO, DLCO/VA and $LCI_{2.5\%}$ did not show any significant differences between children and adolescents with severe, non-severe or asymptomatic infection six months prior to the assessment.




Figure 2: Depiction of **A** FVC Z-score and **B** MEF_{75} Z-score of all participants (COVID-19 and controls) divided into severe, non-severe and asymptomatic infection, respectively no infection in the control group. Boxplots show medians, quartiles, minimum and maximum values. The dots represent the individual values of participants.

FVC, Forced Vital Capacity; MEF_{75} , Mean Expiratory Flow at 75%

Overall, 16.4% ($n = 12$) of the children and adolescents after COVID-19 infection had abnormal pulmonary function compared to 27.7% ($n = 12$) without SARS-CoV-2 infection (OR 0.54, 95% CI 0.22–1.34). Comparing all subjects with and without abnormal pulmonary function, no influence of SARS-CoV-2 status, previous or current pulmonary disease, symptomatic infection or severity of infection was found. Most abnormal pulmonary functions occurred in the 5–8-years age group (see Table 3). This effect was mainly visible in the measurements of $LCI_{2.5\%}$ and FVC (see Figure 3). Two of the eight patients reporting persistent respiratory complaints, and three of the ten suffering fatigue syndrome showed abnormal pulmonary function.

Table 3: Characteristics of participants with and without abnormal¹ pulmonary function

Participant characteristic	Abnormal pulmonary function	Normal pulmonary function	OR (95% CI)
N	24	94	
Positive SARS-CoV-2 status	12 (50)	61 (64.9)	0.54 (0.22–1.34)
Sex, female	10 (41.7)	56 (59.6)	0.48 (0.2–1.2)
Age, years, mean ± SD	8.63 (± 3.7)	10.99 (± 3.1)	
Age group, 5–8 years	17 (70.8)	22 (23.4)	7.95 (2.92–21.63)
Age group, 9–12 years	3 (12.5)	42 (44.7)	0.18 (0.05–0.63)
Age group, 13–18 years	4 (16.7)	30 (31.9)	0.43 (0.13–1.36)
Gestational age, premature	3 (12.5)	6 (6.4)	2.1 (0.48–9.07)
Neonatal intensive care unit	3 (12.5)	14 (14.9)	0.82 (0.21–3.11)
With oxygen supplementation	2 (8.3)	3 (3.2)	2.76 (0.43–17.52)
Pulmonary disease, previous or current	6 (25)	21 (22.3)	1.16 (0.41–3.29)
Infection within 6 months prior to assessment	9 (37.5)	32 (34)	1.16 (0.46–2.95)
With severe infection	4 (16.7)	6 (6.4)	2.93 (0.76–11.37)
With hospitalisation	1 (4.2)	3 (3.2)	1.32 (0.13–13.27)

SD, standard deviation; OR, odds ratio; CI, confidence interval

Data are expressed as n (%), unless specified otherwise

¹ Abnormal pulmonary function defined as at least one measured parameter is pathological ($LCl_{2.5\%} > 7.9$, FVC Z-score, FEV_1 Z-score, MEF_{75} Z-score, MEF_{25} Z-score, DLCO Z-score, DLCO/VA Z-score < -1.96) or at least one borderline parameter ($LCl_{2.5\%} > 7.0$, FVC Z-score, FEV_1 Z-score, MEF_{75} Z-score, MEF_{25} Z-score, DLCO Z-score, DLCO/VA Z-score $< -1 \geq -1.96$) in two different pulmonary function tests (N_2 multiple-breath washout, body plethysmography, diffusion capacity).

$LCl_{2.5\%}$, Lung Clearance Index at 2.5% of starting concentration; FVC, Forced Vital Capacity; FEV_1 , Forced Expiratory Volume in the first Second; MEF, Mean Expiratory Flows at different pulmonary volume levels (75, 25); DLCO, Diffusing Capacity of the lungs for Carbon Monoxide; VA, Alveolar Volume




Figure 3: Scatter plot with **A** LCI_{2.5%} (absolute) and **B** FVC Z-score shown on the x-axis and age in years depicted on the y-axis. Patients after COVID-19 infection are depicted as blue dots, controls are marked as red triangles.

A The dotted lines mark LCI_{2.5%} of 7.0 and 7.9. Values >7.0 are borderline. Values >7.9 are pathological.

B The dotted lines mark FVC Z-score of -1.96 and -1. Values <-1 are borderline. Values <-1.96 are pathological.

LCI_{2.5%}, Lung Clearance Index at 2.5% of starting concentration; FVC, Forced Vital Capacity

Only one child with pneumonia underwent pulmonary imaging during acute COVID-19 infection. No other child or adolescent required imaging of the lungs based on medical assessment.

DISCUSSION

Pulmonary involvement, including severe interstitial pneumonia and acute respiratory distress syndrome (ARDS), in SARS-CoV-2 infections has been the cause of high mortality and long-lasting morbidity in adults [7, 14]. In children and adolescents, severe pulmonary complications are rare [15], even though 11.1% of our patients with symptomatic SARS-CoV-2 infection described dyspnoea with acute COVID-19.

Most SARS-CoV-2 infections in our cohort, however, were asymptomatic during the acute phase. Only 35.6% of patients in our COVID-19 group stated to having had any symptoms during acute infection; respiratory symptoms were reported in 26%. In an Italian cohort with children and adolescents ($n = 16$), 87% showed symptoms at the time of diagnosis of SARS-CoV-2, 19% presenting with respiratory symptoms [8].

Long-term pulmonary symptoms persistent or emerging more than four weeks after the acute infection such as cough, dyspnoea or hyperreactive airways were described by 11.4% of our patients. This is similar to the findings of an Italian cohort study, in which 14.7% of the children had persistent respiratory problems for several months after COVID-19 infection [4]. In adults, frequency of persistent dyspnoea three months after discharge from hospital varies from 9% [16] to 54% [5]. Persistent pulmonary problems after viral infections are a well-known phenomenon in children: for example, children with respiratory syncytial virus (RSV) bronchiolitis show more wheezing episodes in the following 12 months [17] and even up to the age of six years, children with lower respiratory tract RSV infection in early childhood suffer more frequent wheeze (up to 4.3 times) than children without lower respiratory tract infection [18].

Pulmonary function in hospitalised adults is frequently impaired on discharge: Mo et al. described that 47% of their patients had reduced DLCO, total lung capacity (TLC) was decreased in 25%, 9.1% had impaired FVC and 13.6% showed reduced FEV₁ [6]. But even three to four months after discharge, pulmonary function is still impaired in adults [5, 7, 15, 19, 20]. In a Norwegian cohort, FVC and FEV₁ were reduced in about 10% and diffusion capacity in 24% of hospitalised adults three months after discharge [5]. Qin et al. detected significant differences in DLCO levels between discharged patients with severe and non-severe COVID-19 infection at a three-month follow-up [16]. Even after six months, lower DLCO and TLC were detected in patients with critical disease [19]. A Mexican study investigating the correlation between persistent dyspnoea and pulmonary function reported that patients with persistent dyspnoea had significantly lower FVC, FEV₁ and DLCO values than those without [21].

Pulmonary function impairment in children after SARS-CoV-2 infection is rare, as we could show in our cohort. $LCI_{2.5\%}$ was abnormal in 4.4% of children and adolescents with COVID-19, 7% had reduced FVC and 5.3% showed impaired DLCO. No patient had pathological FEV_1 values after SARS-CoV-2 infection. Even in children and adolescents with persistent respiratory symptoms, pulmonary function was normal in 75% of the subjects. Neither $LCI_{2.5\%}$, FEV_1 , DLCO or DLCO/VA showed any significant differences in patients and controls. These results support the preliminary findings of Bottino et al, in which seven children did not show any abnormalities in spirometry and diffusion capacity about two months after their mild SARS-CoV-2 infection [8]. In our cohort, minimal changes persisted for up to six months only in children and adolescents with more severe infection (SARS-CoV-2 or other infections). Similarly, other studies in children with viral infections, such as RSV or rhinovirus, detected acute and long-term loss of pulmonary function [17, 22, 23]. Other known risk factors for reduced pulmonary capacity such as preterm birth [24] or underlying pulmonary disease had no effects in our cohort.

We did not perform pulmonary imaging in all our patients, but only in the ones with severe pulmonary impairment. One had pneumonia at the time of initial diagnosis consistent with several studies showing radiological changes in children with acute COVID-19 [25, 15]. Fortunately, we did not detect any permanent changes on follow-up imaging.

Limitations of this single-centre design with a rather small sample size include age-dependent inconsistencies in pulmonary function performance, patient-reported symptoms and lack of information on long-term outcome of symptoms in controls. Further, our cohort did not include children and adolescents with critical respiratory involvement during acute COVID-19.

To our knowledge, our study is the first to compare pulmonary function in symptomatic and asymptomatic children and adolescents with and without evidence of SARS-CoV-2 infection; no difference between these two groups was observed. Even most patients with persistent respiratory symptoms did not show impaired lung capacity. Severity of infection proved to be the only predictor for mild pulmonary function changes. To conclude, our findings suggest that children and adolescents after SARS-CoV-2 infection do not suffer from persistent deterioration of respiratory function, including body plethysmography, multiple-breath washout and diffusion capacity testing.

Further studies with a larger, more representative cohort (including patients with critical respiratory involvement) and over a longer period are needed for better understanding of the respiratory long-term impairment after SARS-CoV-2 infection in children and adolescents. The discrepancy between subjective persistent respiratory complaints and normal pulmonary function might be caused by functional respiratory disorders, for example hyperventilation, as already described in adults [26, 27].

Thus, further studies including treadmill testing would be useful and were already initiated in our cohort.

REFERENCES

1. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med* 2021;27(4):626–631.
2. COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and Care Excellence (UK); 2020Dec18.PMID:33555768.
3. Carfi A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19. *JAMA* 2020;324(6):603–605.
4. Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children. *Acta Paediatr* 2021 Apr 9; doi: 10.1111/apa.15870.
5. Lerum TV, Aaløkken TM, Brønstad E, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. *Eur Respir J* 2021;57(4):2003448.
6. Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. *Eur Respir J* 2020;55(6):2001217.
7. Anastasio F, Barbuto S, Scarnecchia E, et al. Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life. *Eur Respir J* 2021 Feb 11:2004015; doi: 10.1183/13993003.04015-2020.
8. Bottino I, Patria MF, Milani GP, et al. Can asymptomatic or non-severe SARS-CoV-2 infection cause medium-term pulmonary sequelae in children? *Frontiers in pediatrics* 2021;9:621019
9. Graham BL, Brusasco V, Burgos F, et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. *Eur Respir J* 2017;49(1):1600016.
10. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005;26(2):319–338.
11. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: The global lung function 2012 equations. *Eur Respir J* 2012;40(6):1324–1343.
12. Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. *Eur Respir J* 2017;50(3):1700010.
13. Robinson PD, Latzin P, Verbanck S, et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. *Eur Respir J* 2013;41(3):507–522. Erratum in: *Eur Respir J* 2013;42(5):1432. Ranganathan, Sarah [corrected to Ranganathan, Sarath].
14. Belli S, Balbi B, Prince I, et al. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. *Eur Respir J* 2020;56(4):2002096.

15. Göttinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health* 2020;4(9):653-661.
16. Qin W, Chen S, Zhang Y, et al. Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at three-month follow-up. *Eur Respir J* 2021 Feb 11:2003677. doi: 10.1183/13993003.03677-2020.
17. Cifuentes L, Caussade S, Villagrán C, et al. Risk factors for recurrent wheezing following acute bronchiolitis: a 12-month follow-up. *Pediatr Pulmonol* 2003;36(4):316–321.
18. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999;354(9178):541–5.
19. Riou M, Marcot C, Oulehri W, et al. Respiratory follow-up after hospitalization for COVID-19: Who and when? *Eur J Clin Invest* 2021 May 17: e13603. doi: 10.1111/eci.13603.
20. Bellan M, Soddu D, Balbo PE, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. *JAMA Netw Open* 2021;4(1):e2036142.
21. Cortés-Telles A, López-Romero S, Figueroa-Hurtado E, et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnoea. *Respir Physiol Neurobiol* 2021;288:103644.
22. Kitcharoensakkul M, Bacharier LB, Schweiger TL, et al. Lung function trajectories and bronchial hyperresponsiveness during childhood following severe RSV bronchiolitis in infancy. *Pediatr Allergy Immunol* 2021;32(3):457–464.
23. Guilbert TW, Singh AM, Danov Z, et al. Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma. *J Allergy Clin Immunol* 2011;128(3):532-8.e1-10.
24. Sonnenschein-van der Voort AM, Arends LR, de Jongste JC, et al. Preterm birth, infant weight gain, and childhood asthma risk: A meta-analysis of 147,000 European children. *J Allergy Clin Immunol* 2014;133(5):1317–1329.
25. Kumar J, Meena J, Yadav A, et al. Radiological findings of COVID-19 in children: A systematic review and meta-analysis. *J Trop Pediatr* 2020 Jul 21;fmaa045. doi: 10.1093/tropej/fmaa045.
26. de Groot EP, Duiverman EJ, Brand PL. Dysfunctional breathing in children with asthma: a rare but relevant comorbidity. *Eur Respir J* 2013;41(5):1068-73.
27. Motiejunaite J, Balagny P, Arnoult F, et al. Hyperventilation: A possible explanation for long-lasting exercise intolerance in mild COVID-19 survivors? *Frontiers in physiology* 2021;11:614590.

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	a) and b) addressed in the abstract	<p>RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included.</p> <p>RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract.</p> <p>RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.</p>	<p>1.1 specified in the abstract</p> <p>1.2 this information is included in the methods section</p> <p>1.3 n.a.</p>
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported	Explained in the introduction		
Objectives	3	State specific objectives, including any prespecified hypotheses	Stated in the last paragraph of the introduction		
Methods					
Study Design	4	Present key elements of study design early in the paper	Presented in methods		

Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Decribed in methods		
Participants	6	<p>(a) <i>Cohort study</i> - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>	<p>a) cohort study: data on the items mentioned are included</p> <p>b) cohort study: data provided</p>	<p>RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>Described in results</p> <p>n,a,</p> <p>n.a.</p>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect	Defined in methods	RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these	Provided in methods

		modifiers. Give diagnostic criteria, if applicable.		cannot be reported, an explanation should be provided.	
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Mentioned in methods		
Bias	9	Describe any efforts to address potential sources of bias	Adressed in methods		
Study size	10	Explain how the study size was arrived at	Explained in methods		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Explained in methods		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how	a) + b) described in methods c) explained in methods d) cohort study, n.a. e) included in the analysis		

		<p>matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p>			
Data access and cleaning methods		..		<p>RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population.</p> <p>RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.</p>	<p>n.a.</p> <p>Described in methods</p>
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	n.a.
Results					
Participants	13	<p>(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed)</p> <p>(b) Give reasons for non-participation at each stage.</p>	a) + b) included in results	RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Detailed description in results

		(c) Consider use of a flow diagram			
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)	a) information given in results b) indicated in results c) included in results		
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures	Cohort study: outcome reported in results		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (<i>e.g.</i> , 95% confidence interval). Make clear which confounders were adjusted for and why they were included	a) + b) Included in results c) n.a.		

		(b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	n.a.		
Discussion					
Key results	18	Summarise key results with reference to study objectives	Included in the paper		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussed in the section	RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	Included in the discussion section
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Data interpretation evaluated in the discussion		
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussed in the final paragraphs		

Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Information provided in the funding section		
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	n.a.

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langan SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.